There are currently 150 Nasdaq-listed biotechnology companies trading at an enterprise value of or below zero, where the value of the company is equal to or less than the amount of cash on its balance sheet. This is the greatest number of businesses in this situation in the sector for 15 years.
- Home
- Uncategorised
- How to identify biotech diamonds in the rough